JP2005529840A - Cns標的モジュレータを使用するcns障害の治療 - Google Patents
Cns標的モジュレータを使用するcns障害の治療 Download PDFInfo
- Publication number
- JP2005529840A JP2005529840A JP2003535718A JP2003535718A JP2005529840A JP 2005529840 A JP2005529840 A JP 2005529840A JP 2003535718 A JP2003535718 A JP 2003535718A JP 2003535718 A JP2003535718 A JP 2003535718A JP 2005529840 A JP2005529840 A JP 2005529840A
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- cns
- therapeutic compound
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *OC(C*N(CC1)CCC1C(c1ccccc1)c1ccccc1)=O Chemical compound *OC(C*N(CC1)CCC1C(c1ccccc1)c1ccccc1)=O 0.000 description 5
- HMZHEECHJWHZJX-UHFFFAOYSA-N CC(C)(C(OC)=O)N Chemical compound CC(C)(C(OC)=O)N HMZHEECHJWHZJX-UHFFFAOYSA-N 0.000 description 1
- LXIPTLKADDDKLX-UHFFFAOYSA-N CCc1nc([IH]c2ccc(C)cc2)ccc1 Chemical compound CCc1nc([IH]c2ccc(C)cc2)ccc1 LXIPTLKADDDKLX-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/12—[b,e]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32970101P | 2001-10-16 | 2001-10-16 | |
US38150702P | 2002-05-17 | 2002-05-17 | |
US41424302P | 2002-09-27 | 2002-09-27 | |
PCT/US2002/032970 WO2003032912A2 (fr) | 2001-10-16 | 2002-10-16 | Traitement de troubles du systeme nerveux central (snc) a l'aide de modulateurs de cible snc |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005529840A true JP2005529840A (ja) | 2005-10-06 |
JP2005529840A5 JP2005529840A5 (fr) | 2006-01-05 |
Family
ID=29716072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003535718A Pending JP2005529840A (ja) | 2001-10-16 | 2002-10-16 | Cns標的モジュレータを使用するcns障害の治療 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20050009730A1 (fr) |
EP (1) | EP1443929A4 (fr) |
JP (1) | JP2005529840A (fr) |
AU (1) | AU2002347906A2 (fr) |
CA (1) | CA2463579A1 (fr) |
WO (1) | WO2003032912A2 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004051600A (ja) * | 2002-07-24 | 2004-02-19 | Iyaku Bunshi Sekkei Kenkyusho:Kk | 造血器型プロスタグランジンd2合成酵素阻害剤 |
JP2005505626A (ja) * | 2001-10-16 | 2005-02-24 | エスティーシー ナラ カンパニー リミテッド | ピペリジン誘導体、これの製造方法及びこれを含む痴呆治療用薬学的組成物 |
JP2007516175A (ja) * | 2003-06-27 | 2007-06-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 三環式デルタオピオイド調節剤 |
JP2014224146A (ja) * | 2007-12-12 | 2014-12-04 | アムジエン・インコーポレーテツド | グリシン輸送体−1阻害薬 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7344702B2 (en) | 2004-02-13 | 2008-03-18 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardial perfusion imaging |
US7355042B2 (en) * | 2001-10-16 | 2008-04-08 | Hypnion, Inc. | Treatment of CNS disorders using CNS target modulators |
JP2006525299A (ja) * | 2003-05-01 | 2006-11-09 | ヴァーナリス リサーチ リミテッド | アゼチジンカルボキサミド誘導体及びcb1レセプター媒介障害の治療におけるその使用 |
GB0312419D0 (en) * | 2003-05-30 | 2003-07-02 | Boots Healthcare Int Ltd | Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess |
US7482460B2 (en) | 2003-12-10 | 2009-01-27 | Hypnion, Inc. | Doxepin analogs and methods of use thereof |
US7326721B2 (en) | 2003-12-10 | 2008-02-05 | Hypnion, Inc. | Doxepin analogs and methods of use thereof |
US7411069B2 (en) * | 2003-12-10 | 2008-08-12 | Hypnion, Inc. | Doxepin analogs and methods of use thereof |
US7524864B2 (en) | 2004-04-23 | 2009-04-28 | Hypnion, Inc. | Methods of treating sleep disorders |
US7485283B2 (en) * | 2004-04-28 | 2009-02-03 | Lantheus Medical Imaging | Contrast agents for myocardial perfusion imaging |
KR20070032785A (ko) * | 2004-07-16 | 2007-03-22 | 교와 핫꼬 고교 가부시끼가이샤 | 수면 장해의 예방 및/또는 치료제 |
US7807828B2 (en) * | 2005-08-11 | 2010-10-05 | Hypnion, Inc. | Olanzapine analogs and methods of use thereof |
SG172685A1 (en) | 2006-06-28 | 2011-07-28 | Amgen Inc | Glycine transporter-1 inhibitors |
US8222419B2 (en) * | 2006-09-29 | 2012-07-17 | Nippon Zoki Pharmaceutical Co., Ltd. | Oxepin derivative |
CA2967254C (fr) | 2008-02-29 | 2019-03-26 | Lantheus Medical Imaging, Inc. | Agents de contraste destine aux applications comprenant l'imagerie du cancer |
EP2419096B1 (fr) | 2009-04-15 | 2019-11-13 | Lantheus Medical Imaging, Inc. | Stabilisation de compositions radiopharmaceutiques à l'aide d'acide ascorbique |
CN101838234B (zh) * | 2009-06-17 | 2012-02-08 | 重庆华邦制药股份有限公司 | 阿法乙酯衍生物的合成方法 |
JP6092628B2 (ja) | 2010-02-08 | 2017-03-08 | ランセウス メディカル イメージング, インコーポレイテッド | 造影剤およびその中間体を合成するための方法および装置 |
CN102311381A (zh) * | 2010-07-06 | 2012-01-11 | 重庆华邦胜凯制药有限公司 | 阿伐乙酯衍生物的合成方法 |
WO2013170655A1 (fr) | 2012-05-16 | 2013-11-21 | Techfields Pharma Co., Ltd. | Compositions de promédicament à forte pénétration et composition pharmaceutique associée pour le traitement d'affections pulmonaires |
AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
CN104447516B (zh) * | 2014-12-15 | 2017-05-31 | 重庆华邦制药有限公司 | 一种阿伐斯丁的制备方法 |
IL254641B2 (en) | 2015-03-26 | 2024-01-01 | Jacqueline M Iversen | Methods and preparations including naproxen and fexofenamide for relieving symptoms of dizziness associated with alcohol consumption |
GB2555264A (en) | 2016-04-15 | 2018-04-25 | Univ Oxford Innovation Ltd | Adenosine receptor modulators for the treatment of circadian rhythm disorders |
EP3391886A1 (fr) | 2017-04-19 | 2018-10-24 | Novartis AG | Utilisation d'un agoniste inverse h3r pour le traitement de trouble du travail par équipes |
CN108558860B (zh) * | 2018-06-04 | 2020-12-25 | 成都伊诺达博医药科技有限公司 | 一种合成芜地溴铵的方法 |
CN110903182A (zh) * | 2018-09-14 | 2020-03-24 | 北京艾德旺科技发展有限公司 | 简单环保的4-氟-2-甲基苯甲酸的化学合成方法 |
MX2022004736A (es) | 2019-10-21 | 2022-07-27 | Alairion Inc | Derivados de acido 3-(4-(11h-dibenzo [b, e] [1, 4] azepin-6-il)piperazin-1-il)- y 3-(4- dibenzo [b, f] [1, 4] oxazepin/tiazepin/diazepin-11-il)piperazin-1-il)propanoico como moduladores de los receptores h1 y 5-ht2a para el tratamiento de los trastornos del sue?o. |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3045023A (en) * | 1960-04-06 | 1962-07-17 | Searle & Co | Dialkylaminoethyl diphenylmethylpiperidinepropionates |
US4072756A (en) * | 1973-05-17 | 1978-02-07 | Sandoz Ltd. | Tricyclo piperidino ketones and soporific compositions thereof |
US4383999A (en) * | 1981-05-26 | 1983-05-17 | Smithkline Beckman Corporation | Inhibition of GABA uptake by N-substituted azaheterocyclic carboxylic acids and their esters |
US4514414A (en) * | 1982-10-25 | 1985-04-30 | Smithkline Beckman Corporation | N-Substituted pyrrolidineacetic acids and their esters |
US4610995A (en) * | 1984-07-27 | 1986-09-09 | Coker Geoffrey G | Certain 1,1-diaryl-propenyl-3-(1-pyrrolidino-2-carboxylic acids, derivatives thereof and their anti-histaminic properties |
DK165692C (da) * | 1986-01-07 | 1993-11-08 | Novo Nordisk As | Phenylbutenderivater, fremgangsmaade til fremstilling heraf, farmaceutisk praeparat indeholdende disse, samt anvendelse af disse til fremstilling af et medikament nyttigt til inhibering af gaba-optagelse i mennesker |
US5231105A (en) * | 1987-06-02 | 1993-07-27 | Ajinomoto Co., Inc. | Ethylamine derivatives and antihypertensives containing the same |
US4829064A (en) * | 1987-06-08 | 1989-05-09 | Analgesic Associates | Cough/cold mixtures comprising non-sedating antihistamine drugs |
US4929618A (en) | 1988-03-25 | 1990-05-29 | Ube Industries, Ltd. | Piperdine and piperazine derivatives, and antihistaminic pharmaceutical compositions containing the same |
US5393890A (en) * | 1988-06-02 | 1995-02-28 | Ajinomoto Co., Inc. | Piperidine derivatives and hypotensives containing the same |
US5250681A (en) * | 1988-06-02 | 1993-10-05 | Ajinomoto Co., Inc. | Piperidine derivatives and hypotensives containing the same |
JPH0812127B2 (ja) * | 1988-11-11 | 1996-02-07 | オリンパス光学工業株式会社 | 曲率半径測定装置及び方法 |
CA2015949A1 (fr) | 1989-05-22 | 1990-11-22 | Yasuo Ito | Derive de piperidine, methode de preparation et compose pharmaceutique le contenant |
US5095022A (en) * | 1989-07-04 | 1992-03-10 | Hokuriku Pharmaceutical Co., Ltd. | Piperidine derivatives and pharmaceutical compositions comprising the same |
JPH03133956A (ja) * | 1989-10-20 | 1991-06-07 | Hokuriku Seiyaku Co Ltd | ピペリジン誘導体 |
JP2624372B2 (ja) * | 1990-11-15 | 1997-06-25 | 宇部興産株式会社 | ジアリールメトキシピペリジン誘導体 |
JPH0517442A (ja) | 1991-07-05 | 1993-01-26 | Hokuriku Seiyaku Co Ltd | ピペリジン誘導体 |
JPH0517443A (ja) | 1991-07-11 | 1993-01-26 | Hokuriku Seiyaku Co Ltd | ピペリジン誘導体 |
JP2625294B2 (ja) | 1991-10-08 | 1997-07-02 | 宇部興産株式会社 | ピペリジン誘導体 |
JP3338913B2 (ja) | 1993-06-29 | 2002-10-28 | 大鵬薬品工業株式会社 | テトラゾール誘導体 |
IL117798A (en) | 1995-04-07 | 2001-11-25 | Schering Plough Corp | Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them |
US5801175A (en) * | 1995-04-07 | 1998-09-01 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
AU7280696A (en) * | 1995-11-03 | 1997-05-29 | Novo Nordisk A/S | A method of treating filariae |
CA2619901A1 (fr) | 1996-05-31 | 1997-12-04 | Allelix Neuroscience Inc. | Produit pharmaceutique pour le traitement de troubles neurologiques et neuropsychiatriques |
US6191165B1 (en) * | 1996-05-31 | 2001-02-20 | Allelix Neuroscience Inc. | Pharmaceutical for treatment of neurological and neuropsychiatric disorders |
TW486475B (en) * | 1996-12-26 | 2002-05-11 | Ube Industries | Acid addition salt of optically active piperidine compound and process for preparing the same |
EP0991633A1 (fr) * | 1997-06-25 | 2000-04-12 | Novo Nordisk A/S | Nouveaux composes heterocycliques |
US6503926B2 (en) * | 1998-09-04 | 2003-01-07 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
US6288083B1 (en) * | 1998-09-04 | 2001-09-11 | Millennium Pharmaceuticals, Inc. | Chemokine receptor antagonists and methods of use therefor |
DE19840611A1 (de) | 1998-09-05 | 2000-03-09 | Klaus Wanner | GABA-uptake-Inhibitoren mit Pyrrolidinstruktur |
US6387930B1 (en) * | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
EP1202721A1 (fr) * | 1999-08-13 | 2002-05-08 | Vela Pharmaceuticals Inc. | Cyclobenzaprine permettant de traiter des troubles de l'anxiete generalises et compositions a base de celle-ci |
JP3909998B2 (ja) | 2000-03-22 | 2007-04-25 | 田辺製薬株式会社 | 経口投与製剤 |
KR100579813B1 (ko) | 2001-10-16 | 2006-05-12 | 주식회사 에스티씨나라 | 피페리딘 유도체, 이의 제조방법 및 이를 포함하는 치매치료용 약학적 조성물 |
JP4550353B2 (ja) | 2002-07-24 | 2010-09-22 | 株式会社医薬分子設計研究所 | 造血器型プロスタグランジンd2合成酵素阻害剤 |
-
2002
- 2002-10-16 CA CA002463579A patent/CA2463579A1/fr not_active Abandoned
- 2002-10-16 EP EP02784116A patent/EP1443929A4/fr not_active Withdrawn
- 2002-10-16 WO PCT/US2002/032970 patent/WO2003032912A2/fr active Application Filing
- 2002-10-16 US US10/492,990 patent/US20050009730A1/en not_active Abandoned
- 2002-10-16 AU AU2002347906A patent/AU2002347906A2/en not_active Abandoned
- 2002-10-16 JP JP2003535718A patent/JP2005529840A/ja active Pending
-
2003
- 2003-12-04 US US10/728,340 patent/US7317026B2/en not_active Expired - Fee Related
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005505626A (ja) * | 2001-10-16 | 2005-02-24 | エスティーシー ナラ カンパニー リミテッド | ピペリジン誘導体、これの製造方法及びこれを含む痴呆治療用薬学的組成物 |
JP2004051600A (ja) * | 2002-07-24 | 2004-02-19 | Iyaku Bunshi Sekkei Kenkyusho:Kk | 造血器型プロスタグランジンd2合成酵素阻害剤 |
JP4550353B2 (ja) * | 2002-07-24 | 2010-09-22 | 株式会社医薬分子設計研究所 | 造血器型プロスタグランジンd2合成酵素阻害剤 |
JP2007516175A (ja) * | 2003-06-27 | 2007-06-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 三環式デルタオピオイド調節剤 |
JP4810423B2 (ja) * | 2003-06-27 | 2011-11-09 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 三環式デルタオピオイド調節剤 |
JP2014224146A (ja) * | 2007-12-12 | 2014-12-04 | アムジエン・インコーポレーテツド | グリシン輸送体−1阻害薬 |
Also Published As
Publication number | Publication date |
---|---|
WO2003032912A3 (fr) | 2003-12-11 |
WO2003032912A8 (fr) | 2004-08-19 |
US7317026B2 (en) | 2008-01-08 |
US20050009730A1 (en) | 2005-01-13 |
EP1443929A4 (fr) | 2008-02-06 |
WO2003032912A2 (fr) | 2003-04-24 |
EP1443929A2 (fr) | 2004-08-11 |
AU2002347906A2 (en) | 2003-04-28 |
CA2463579A1 (fr) | 2003-04-24 |
US20040142972A1 (en) | 2004-07-22 |
WO2003032912A9 (fr) | 2005-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2005529840A (ja) | Cns標的モジュレータを使用するcns障害の治療 | |
US7355042B2 (en) | Treatment of CNS disorders using CNS target modulators | |
JP2007534696A5 (fr) | ||
US20040259842A1 (en) | Intracellular calcuim concentration increase inhibitors | |
AU2003210598A1 (en) | Treatment of sleep disorders using sleep target modulators | |
JP2008503523A (ja) | 苦痛、うつ病及び(又は)不安障害の治療に使用するための飽和及び不飽和3−ピリジル−ベンゾシクロアルキルメチル−アミン類 | |
JPH0673038A (ja) | ビフェニル誘導体、これらの化合物を含む医薬組成物及びそれらの調製法 | |
US7189757B2 (en) | Treatment of sleep disorders using CNS target modulators | |
AU2005296674B2 (en) | Ester derivative and pharmaceutical use thereof | |
US8101774B2 (en) | Ester derivatives and medicinal use thereof | |
JPH06511231A (ja) | 2−(ピロリジニル−1−メチル)−ピペリジン誘導体およびκ受容体アゴニストとしてのその使用 | |
JP2000514427A (ja) | フィブリノーゲンレセプター拮抗薬プロドラッグ | |
JPH10513479A (ja) | 芳香環にフェニル置換基を有するテトラリン、および癲癇、卒中、および脳または脊髄外傷の処置におけるその使用 | |
JP5060133B2 (ja) | エステル誘導体及びその医薬用途 | |
JPH03141257A (ja) | ジヒドロピリジン誘導体 | |
JPH03181419A (ja) | イミダゾピリジンを含有する麻酔薬 | |
CN101056628B (zh) | 酯衍生物及其医药用途 | |
JPH10287637A (ja) | アミジン誘導体 | |
JPH01238569A (ja) | ジヒドロピリジン誘導体 | |
JPH01100159A (ja) | アミド化合物 | |
WO1996031481A1 (fr) | Nouveaux composes heterocycliques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051012 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051012 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081211 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090612 |